TACC3 and central nervous system cancer: The tyrosine kinase inhibitors AZD4547, PD173074, BGJ398, and JNJ-42756493 inhibited the proliferation of FGFR3-TACC3 transfected astrocytes in vitro and led to reduced tumor growth and prolonged survival in glioma-bearing mice [10,11,39,76].